Proactive - Interviews for investors

Zero Candida celebrates TSX Venture listing and debuts treatment for recurrent yeast infections

Zero Candida Co-Founder and CEO Eli Ben-Haroosh joined Steve Darling from Proactive to mark a significant milestone as the company opened the market in celebration of its listing on the TSX Venture Exchange under the ticker symbol ZCT. The listing highlights the company’s mission to revolutionize women’s health with its groundbreaking technology. Zero Candida’s patented innovation leverages controlled “Blue Light” technology to effectively destroy fungal infections at unprecedented speed and without side effects. Delivered via a tampon-like medical device, this novel treatment offers a comprehensive solution for eliminating vulvovaginal candidiasis (VVC) and preventing its recurrence. VVC, commonly known as yeast infection, affects approximately 75% of women during their reproductive years. For 8-10% of women, these infections are recurrent, with four or more episodes annually. Globally, 138 million women face recurrent infections every year, a number expected to rise to 158 million by 2030. Key factors contributing to recurrent VVC include antibiotic use, hormonal changes, and sexual activity. Zero Candida’s innovative approach seeks to meet the unmet needs of this growing demographic, offering a safer and more effective alternative to current treatments. According to Ben-Haroosh, Zero Candida’s technology represents a major advancement in the FemTech sector, providing a transformative solution for women’s health challenges. With its public listing, the company is well-positioned to accelerate its mission of improving outcomes for millions of women globally. #proactiveinvestors #zerocandida #tsxv #zct #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Duration:: 7m
Broadcast on:: 02 Dec 2024
Audio Format:: other

All right. Welcome back inside our proactive newsroom. Joining me now is Eli Ben Harushi is the CEO and co-founder of Zero Candida. Eli, good to see you. How are you? I'm doing the thanks for having me here today. I'm much appreciated for the time. Everything is okay. We're doing well. We're moving forward. Excellent. Well, that's good to hear. Let's talk all about it because the company has most recently listed on the TSX Venture Exchange, getting on the market. Let's start there. Let's actually take a step back and tell everyone a little bit about the company itself. Zero Candida is basically innovation and a startup with enormous knowledge inside that device we're going to develop. It's AI device with a future for the next generation, the communication between the patient, the doctor woman, and the patient. So we will not only treat with non-drug treatment in the cadida. Finally, we also brought for the woman health a new generation between the communication or the new future of health for women. Zero Candida started in 2022 and we provide, since then, research. We start with a small company. Now we have two laboratories, one in Europe and one in Israel. The one in Europe do this C standard and the one in Israel do the FDA startup with the cooperation with the FDA registration we did. So in the team, we have inside microbiology, we have chemistry, PhD, we have laboratories, we have our own equipment to grow the Candida in lab terms and kill it with the device. Day after day, we do it with 99.999% successfully overnight. That's amazing non-drug treatment. Boundary treatment is the new generation of treatment for women around the world. So just so people understand, this pad the technology that you have for people more familiar with the term, it basically is combating yeast infections in women which is very common all over the world as a matter of fact. So that's really what this is and using the blue light instead of what's currently on which is some sort of medical treatment, using some sort of topicals or things like that. Yes it is. First of all, the Candida's, is 75% for all women population in the world have at least once of a life or two from that event of Candida. And trust me, see there is no one-night treatment. There is no. The treatment today with the cream or pills or anything that provide the market is taking weeks even months to get rid of that fungus and she come back. She come back again and again and again and she attacked again the area of in the vagina. So we developed the blue light therapy with a very special pulse and we go inside with our device, small device like a backbone and we only kill the fungus. The all other probiotics that have inside the vagina that very important for the woman, we won't touch it. So the zero Candida device go directly for the fungus and kill it overnight even less than night, three hours. So after it, she will feel 100% cure. She will feel that the fungus is gone. Then the device will remind her after seven days to check again and the device will do the agonos back to the vagina and do the agonos and then the old data go directly from there our device by CRM to her doctor. She didn't even love to call it. We will call her. They after the say, "Hey, I saw the device. I saw the treatment. I got the report and I analyzed it and come back to you." So the doctor will talk directly with the device. That's the future. Yeah. What stage you're at right now in development? I know that you mentioned you've had a number of studies which you have published already. So where are you as far as the next stage of where you want to go? Well, at the moment we are finishing the final growth for the human trial, we are already finishing the preclinical animal safety, 100% safety device with the pilot with chip. This is the animal the FDA chose for us. We're going back to final device. We're going to complete it probably by the Q1 of 2025 and provide it another safety trial. By the end of 2025 Q3, I want to start a clinical trial. The clinical trial is going to be 200 women around the world. It's going to be about 100 to Israel and the rest in USA. So we're going to provide to the FDA the matching group of women that we can cover where they can be the funders. Okay. And lastly, as I mentioned, you're now listed on the TSX venture listing under the symbol ZCT. So obviously this is a key moment for the company in getting into the capital markets. Yes, it is. It's a celebration. We just saw a week ago and we started trade in November 25. The share is about above $2 per share and we're doing well. We have a lot of interest in this company. For Canada also, kind of from Europe, Germany and USA. My plan is to complete double listing for the OTCQ in probably in the beginning of January 2025. So then we can provide to American investors to join our company. During these times, we're going to also allow us to go to Frankfurt exchange. It's going to be a listing much easier for the company. And then we complete the triple trade in Canada, TXV, OTCQ and the front food exchange. That's okay. Well, Eli, thank you so much. Important work you're doing. I read that by 2030, 158 million women will be affected by recurring yeast infections. So obviously, it's super important work that you are doing in a large market as well. So appreciate your time. Thank you very much. Thank you. And I want to say a final four zero could be that in the future, zero can be that we're not stopping can be that treatment. We're going to develop a new treatment like you said in the in the 2030 is going to be 150 billion. So we're going to bring and more and more households for the world how we can treat better for women. It's a fair tech technology period. 100%. Thank you for that. And thank you. Well said Eli Ben Harris, the CEO and co-founder of zero Candida.